10x Genomics, Inc. (BMV:TXG)

10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of MXN 49.09 billion. The enterprise value is 42.14 billion.

Market Cap	49.09B
Enterprise Value	42.14B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	116.47M
Shares Outstanding	n/a
Shares Change (YoY)	+3.07%
Shares Change (QoQ)	+0.80%
Owned by Insiders (%)	8.14%
Owned by Institutions (%)	97.92%
Float	114.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.17
PB Ratio	3.41
P/TBV Ratio	3.74
P/FCF Ratio	32.78
P/OCF Ratio	30.23
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-30.10
EV / Sales	3.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	28.14

Financial Position

The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.11.

Current Ratio	4.48
Quick Ratio	3.93
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	1.07
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -10.12% and return on invested capital (ROIC) is -9.85%.

Return on Equity (ROE)	-10.12%
Return on Assets (ROA)	-8.42%
Return on Invested Capital (ROIC)	-9.85%
Return on Capital Employed (ROCE)	-15.04%
Revenue Per Employee	9.01M
Profits Per Employee	-1.07M
Employee Count	1,306
Asset Turnover	0.65
Inventory Turnover	2.56

Taxes

In the past 12 months, 10x Genomics has paid 59.17 million in taxes.

Income Tax	59.17M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.50% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-17.50%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	27.78
Average Volume (20 Days)	710

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.67

Income Statement

In the last 12 months, 10x Genomics had revenue of MXN 11.77 billion and -1.40 billion in losses. Loss per share was -11.35.

Revenue	11.77B
Gross Profit	8.12B
Operating Income	-2.43B
Pretax Income	-1.34B
Net Income	-1.40B
EBITDA	-1.79B
EBIT	-2.43B
Loss Per Share	-11.35

Balance Sheet

The company has 8.84 billion in cash and 1.60 billion in debt, with a net cash position of 7.25 billion.

Cash & Cash Equivalents	8.84B
Total Debt	1.60B
Net Cash	7.25B
Net Cash Per Share	n/a
Equity (Book Value)	14.40B
Book Value Per Share	113.80
Working Capital	9.40B

Cash Flow

In the last 12 months, operating cash flow was 1.62 billion and capital expenditures -126.08 million, giving a free cash flow of 1.50 billion.

Operating Cash Flow	1.62B
Capital Expenditures	-126.08M
Free Cash Flow	1.50B
FCF Per Share	n/a

Margins

Gross margin is 68.94%, with operating and profit margins of -20.63% and -11.89%.

Gross Margin	68.94%
Operating Margin	-20.63%
Pretax Margin	-11.39%
Profit Margin	-11.89%
EBITDA Margin	-15.19%
EBIT Margin	-20.63%
FCF Margin	12.72%

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.07%
Shareholder Yield	-3.07%
Earnings Yield	-2.85%
FCF Yield	3.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

10x Genomics has an Altman Z-Score of 2.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.6
Piotroski F-Score	3